Biochemical Engineering Special Interest Group
biological engineering professionals
12 October 2016

Adaptimmune stock slides after poor T-cell efficacy

Adaptimmune has responded to the failure of its T-cell therapy to induce objective clinical responses in ovarian cancer patients by adding fludarabine--the drug linked to deaths in a Juno Therapeutics trial--to the preconditioning regimen. Investors reacted to the lack of efficacy and addition of fludarabine by driving down Adaptimune’s share price by 12%. Source: FierceBiotech 12/10/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).